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Original article
Impact of TNF inhibitor therapy on joint replacement
rates in rheumatoid arthritis: a matched cohort
analysis of BSRBR-RA UK registry data
Samuel Hawley1, M. Sanni Ali1,2, Ren e Cordtz3,4, Lene Dreyer5,6,
Christopher J. Edwards7, Nigel K. Arden8,9, Cyrus Cooper8,9, Andrew Judge1,9,10,
Kimme Hyrich 11,12 and Daniel Prieto-Alhambra1,13
Abstract
Objectives. Previous ecological data suggest a decline in the need for joint replacements in RA patients following the
introduction of TNF inhibitor (TNFi) therapy, although patient-level data are lacking. Our primary aim was to estimate the
association between TNFi use and subsequent incidence of total hip replacement (THR) and total knee replacement.
Methods. A propensity score matched cohort was analysed using the British Society for Rheumatology Biologics
Registry (20012016) for RA data. Propensity score estimates were used to match TNFi users to similar conventional
synthetic DMARD users (with replacement) using a 1:1 ratio. Weighted multivariable Cox regression was used to estimate
the impact of TNFi on study outcomes. Effect modification by baseline age and disease severity were investigated. Joint
replacement at other sites was also analysed. An instrumental variable sensitivity analysis was also performed.
Results. The matched analysis contained a total of 19 116 patient records. Overall, there was no significant association
between TNFi use vs conventional synthetic DMARD on rates of THR (hazard ratios = 0.86 [95% CI: 0.60, 1.22]) although
there was significant effect modification by age (P < 0.001). TNFi was associated with a reduction in THR among those
>60 years old (hazard ratio = 0.60 [CI: 0.41, 0.87]) but not in younger patients. No significant associations were found for
total knee replacement or other joint replacement.
Conclusion. Overall, no association was found between the use of TNFi and subsequent incidence of joint replace-
ment. However, TNFi was associated with a 40% relative reduction in THR rates among older patients.
Key words: epidemiology, rheumatoid arthritis, biologics, TNF inhibitor, joint replacement, total hip replace-
ment, total knee replacement, comparative effectiveness
Rheumatology key messages
. Overall TNFi use was not associated with subsequent rates of joint replacement.
. Among elderly patients, TNFi use was associated with a 40% reduction in subsequent THR rates.
. Given prior ecological data, future studies are needed to confirm and/or further elucidate the relationship between
TNFi and joint replacement.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease driven by pathological inflammatory processes in
patients’ joints, subsequent hallmarks of which include
structural damage to cartilage and bone [13]. Joint
damage is a central feature of RA and has been estimated
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to account for 25% of disability in established disease
[4]. The permanent and often progressive nature of joint
damage, in conjunction with associated pain, loss of func-
tion and failure to adequately respond to therapeutic op-
tions are strong indications for eventual joint replacement
surgery [5, 6]. Outcomes for hip and knee replacement in
RA are generally considered good [7], although it has been
observed that such patients are at increased risk of vari-
ous adverse events compared with patients undergoing
these procedures for osteoarthritis, including dislocation,
infection, myocardial infarction and revision [8, 9].
Furthermore, there are significant healthcare costs,
which in the UK are £6000  £7000 per operation [10].
The prevention of irreversible joint damage through early
and aggressive management using pharmacotherapy has
been well demonstrated and is therefore recommended in
numerous national guidelines [1113]. First-line therapy
options include various conventional synthetic DMARDs
(csDMARDs).
Over recent decades, the emergence of biologic thera-
pies such as TNF inhibitors (TNFi) has revolutionized the
management of RA as these drugs are widely recognized
to improve numerous outcomes of the disease, including
joint damage [14, 15]. Despite this, to our knowledge there
are no randomised controlled trials (RCT) studies address-
ing the issue of whether biologic therapies prevent/delay
ultimate joint failure, as indicated by the need for a joint
replacement. Recent ecological data from the UK and
Denmark have indicated a reduction in the incidence of
knee replacement among RA patients following the intro-
duction of TNFi in 2002/2003 [16, 17], however concurrent
to this has been an increasing emphasis on early and
more aggressive usage of csDMARDs. Patient-level data
on this topic is required to disentangle these issues, yet
such data remain scarce.
Our current aim was to estimate the comparative effect-
iveness of TNFi vs csDMARDs on subsequent rates of
total hip replacement (THR) and total knee replacement
(TKR) among a large cohort of RA patients.
Methods
Data sources and exposures
We obtained data from the British Society for
Rheumatology Biologics Register for RA (BSRBR-RA).
This register contains prospectively collected observational
data on over 20 000 RA patients recruited from 2001 on-
wards, primarily in order to evaluate the real-world safety of
TNFi. The initial UK national institute for health and care
excellence (NICE) guidance on use of TNFi stipulated clin-
icians initiating such therapy must register the patient into
the BSRBR-RA, and recruitment continued originally until
the target of at least 4000 patients per TNFi cohort (etaner-
cept, infliximab or adalimumab) was reached (last ‘original’
patient recruited 2008) but reopened recruitment to these
three originator drugs from 2010 onwards. NICE guidance
restricts National Health Service prescribing of TNFi to pa-
tients with a sustained 28-joint DAS (DAS28) >5.1 who
have failed to adequately respond to two csDMARDs,
with each treatment lasting 56 months. The BSRBR-RA
contains an additional comparator cohort of non-biologic
treated RA patients on csDMARDs, entry into which was
dependent on having active disease (guide DAS28> 4.2).
Recruitment to this cohort closed in 2008.
Participants in all study cohorts are followed up indef-
initely using physician questionnaires sent from BSRBR-
RA to the patients’ rheumatology clinic. These were sent
every six months for a patients’ first three years of follow-
up, and annually thereafter. In addition to collecting data
on changes to therapy and disease details, physicians
were asked what serious/adverse events had occurred
since the last follow-up date. In addition, patients were
asked to complete a health diary every six months for
the first three years in the study in which they detailed
any hospital admissions. These free text responses were
coded by BSRBR-RA staff using the MedDRA hierarchy
(Medical Dictionary for Regulatory Activities [18]).
Mortality data for participants were obtained from the
Health and Social Care Information Centre (now merged
into NHS digital) via alerts generated from Office for
National Statistics records. The BSRBR has ethical ap-
proval from the North West Multicentre Research Ethics
Committee (reference number MREC 00/08/053) and pa-
tients gave written informed consent to participate in the
BSRBR; no further ethical approvals were required to
undertake this analysis.
Outcomes
The primary outcomes of interest were first occurrence of
THR or TKR, analysed separately. Patients were followed
up from date of registration into BSRBR-RA until the ear-
liest date of either outcome event, follow-up form date
indicating change in TNFi exposure status (stopping
among TNFi users or starting biologics among csDMARD
users), last follow-up form or death. Other joint replace-
ment (OJR) (a composite outcome consisting of elbow,
shoulder, hand or other small joint replacement) was a sec-
ondary outcome.
Study population
Our study sample (Supplementary File 1, available at
Rheumatology online) consisted of all biologic-naı¨ve RA
patients, either in the control cohort or those initiating a
TNFi (etanercept, infliximab or adalimumab) no more than
6 months prior to registration within BSRBR-RA. Patients
with a THR or TKR recorded prior to registration were
excluded, as were patients with <6 months of follow-up
(i.e. those who did not return at least one follow-up ques-
tionnaire). In analyses of OJR, further exclusion was made
of patients who had undergone an OJR prior to baseline.
Statistical analysis
Owing to confounding by indication, i.e. TNFi users vs
csDMARD users likely having a different baseline risk of
THR/TKR, we decided a priori to match TNFi users to
csDMARD users based on their propensity for receiving
treatment. Propensity scores (PS), i.e. the probability of
receiving treatment conditional on observed baseline
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characteristics (including those predictive of outcome)
were estimated for all patients using logistic regression.
The list of potential confounders included in the PS equa-
tion (and described in Table 1) consisted of: age, gender,
ethnicity, index of multiple deprivation (socio-economic
status), BMI, smoking status, year of registration (quin-
tiles), time since RA diagnosis, DAS28, HAQ score, quality
of life (SF36 domains), 1987 ACR criteria, systemic in-
volvement, co-morbidities and co-medications. A full de-
scription of these variables are included in Supplementary
File 2, available at Rheumatology online. We matched
each TNFi patient to the csDMARD patient with the
most similar PS within a caliper distance of 0.2 standard
deviations of the logit of the PS [19]. Patients falling out-
side this common support region remained unmatched
and were excluded from further analysis. We used
matching with replacement [20] owing to fewer available
csDMARD patients than TNFi users in the register.
Missing data were imputed using chained equations and
10 imputed datasets were created. Statistical analyses
were carried out in Stata 15.1 and R.
Baseline characteristics of the TNFi user and csDMARD
cohorts were summarized and differences assessed by
way of standardized mean differences [21, 22], with smal-
ler values indicative of greater similarity between cohorts.
This assessment was carried out for the cohort prior to
matching and in the 10th imputed dataset. Incidence rates
of each outcome event with 95% CIs were calculated
among matched TNFi users and csDMARD users.
Weighted Cox regression was used to compare THR,
TKR and OJR rates, taking into account the number of
times each individual csDMARD user was included by
TABLE 1 Baseline characteristics of propensity score matched cohortsa: stratified by use of TNFi vs conventional
synthetic DMARDs
CS-DMARD (n = 9558) (1644 unique patients) TNFi (n = 9558)
Characteristic n % n % SMD
Age, mean (S.D.) 55.2 (12.1) 55.2 (12.3) 0
Gender: female, % 7289 76.3 7259 75.9 0.01
Ethnicity: white/Caucasian, % 9114 95.4 9118 95.4 0.00
Index multiple deprivation
Quintile 1 1282 13.4 1322 13.8 0.01
Quintile 2 1420 14.9 1485 15.5 0.02
Quintile 3 1413 14.8 1640 17.2 0.07
Quintile 4 1544 16.2 1710 17.9 0.05
Quintile 5 1284 13.4 1650 17.3 0.11
Unknown 2615 27.4 1751 18.3 0.22
BMI 26.8 (5.9) 27.1 (6.3) 0.06
Smoking?
% Current 2448 25.6 2259 23.6 0.05
% Ex 3272 34.2 3577 37.4 0.07
Calendar period of registration
Oct 01Oct 03 1481 15.5 2262 23.7 0.21
Nov 03Aug 04 2037 21.3 2037 21.3 0
Sept 04Aug 05 1823 19.1 1802 18.9 0.01
Aug 05May 07 1664 17.4 1462 15.3 0.06
May 07May 16 2553 26.7 1995 20.9 0.14
Years since diagnosis, median (IQR) 10.8 (10.7) 11.0 (8.8) 0.02
DAS 28, mean (S.D.) 6.47 (1.09) 6.43 (0.98) 0.04
Overall HAQ score 1.91 (0.63) 1.91 (0.62) 0.01
ACR: ever rheumatoid positive, % 5532 57.9 6055 63.4 0.11
ACR deformity of 53 joint areas?, % 7425 77.7 8118 84.9 0.19
ACR: erosions on hands/feet, % 4651 48.7 5282 55.3 0.13
ACR: ever had nodules, % 4034 42.2 3988 41.7 0.01
ACR: symmetry, % 7468 78.1 7883 82.5 0.11
ACR: deformity of hand joint, % 6771 70.8 7602 79.5 0.20
ACR: morning stiffness >1 h, % 8901 93.1 8966 93.8 0.03
Non-major prior joint replacementb 1742 18.2 1989 20.8 0.07
aResults shown are for the 10th imputed dataset. Matching was performed using replacement of the cs-DMARD users. 9558
biologic users were each matched to one of the 3229 cs-DMARD users (with replacement). Number of csDMARD patients
represented in final matched sample was 1644. bComposite variable consisting of: shoulder, elbow, neck or other small joint
replacement (e.g. hand). SMD: standardized mean difference (smaller values indicative of better balance).
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the matching with replacement, and adjusting the stand-
ard error of the estimates accordingly. We censored all
patients at 12 years due to the small and unstable size
of the csDMARD cohort after this time. Baseline charac-
teristics that were not sufficiently similar post-matching,
defined as standardized mean difference >0.1 (21), were
entered into a final multivariable Cox model for further
adjustment [23]. Final models were run for all 10 datasets
created in the multiple imputation process and hazard
ratios (HRs) were pooled using Rubin’s rules.
Age and disease severity were a priori specified as po-
tential effect modifiers of the association between TNFi
use and subsequent need for joint replacement. We
tested for these by including interaction terms for approxi-
mately median age (</560 years old) and DAS28 (4/>5.1
NICE cut-off) in the weighted Cox model and used the
likelihood ratio test to assess model fit. In the event of a
significant interaction (P < 0.1), matching and survival
models were re-run stratified by the significant effect
modifier.
Sensitivity analyses
We addressed the potential of unobserved confounding
through the use of an instrumental variable (IV) approach,
using physician preference as the instrument, as has been
done previously [24, 25]. Details of this sensitivity analysis
are described in Supplementary File 3, available at
Rheumatology online. We also repeated the main PS ana-
lysis after excluding TNFi users recruited into the registry
after the csDMARD cohort had closed, in order to max-
imize comparability between groups.
Results
Of 13 126 eligible RA patients identified in BSRBR-RA,
97% (9558) of the TNFi users and 51% (1644) of the
csDMARD users were retained following PS matching
(Supplementary File 1, available at Rheumatology
online). Given the 1:1 matching with replacement, a total
of 19 116 patient records were used in subsequent ana-
lyses, with each csDMARD user being used a median of
three (interquartile range (IQR): 16) times.
Baseline characteristics of TNFi users were markedly
different in the unmatched study sample compared with
the csDMARD cohort (Supplementary File 2, available at
Rheumatology online), especially in aspects of disease
severity. Specifically, the TNFi cohort had on average
higher DAS28, HAQ score, proportion fulfilling the 1987
ACR RA criteria, lower health-related quality of life (as
per SF36), longer disease duration and a higher preva-
lence of prior non-major joint replacement. Conversely,
baseline characteristics between exposure cohorts were
much more similar post-matching (Table 1). The only per-
sisting differences (standardized mean difference> 0.1)
between the matched cohorts were calendar period of
registration, low deprivation and the proportion of patients
fulfilling ACR criteria.
Total hip replacement
A total of 589 THRs were reported during follow-up
(median = 4.94 years [IQR: 1.5210.04] for TNFi and
5.97 years [IQR: 2.059.55] for csDMARD) of the propen-
sity-matched cohorts. Incidence rates (per 1000 PYs)
were 5.22 [95% CI: 4.66, 5.88] and 6.30 (95% CI: 4.24,
9.76) among TNFi users and csDMARD users, respect-
ively (Supplementary File 4, available at Rheumatology
online).
Comparing TNFi to csDMARDs yielded a pooled HR =
0.91 [95% CI: 0.64, 1.31; P = 0.62], which when adjusted
for any remaining post-matching imbalance in baseline
covariates was 0.86 [95% CI: 0.60, 1.22; P = 0.39] (Fig. 1).
Total knee replacement
Among the matched sample, a total of 864 TKRs were
reported during followup (median = 4.85 years [IQR:
1.5010.01] for TNFi and 5.98 years [IQR: 2.039.55] for
csDMARD) of the propensity-matched cohorts. Incidence
rates (per 1000 PYs) were 8.89 [95% CI: 8.13, 9.72] and
8.09 [95% CI: 5.32, 12.89] among TNFi users and
csDMARD users, respectively (Supplementary File 4,
available at Rheumatology online). This yielded a pooled
HR = 1.18 [95% CI: 0.90, 1.56; P = 0.24], which when
adjusted for any remaining post-matching imbalance in
baseline covariates was 1.11 [95% CI: 0.84, 1.47; P =
0.46] (Fig. 1).
Other joint replacement
Among the matched sample, a total of 336 OJRs occurred
during follow-up (median = 4.93 years [IQR: 1.5210.02]
for TNFi and 5.98 years [IQR: 2.059.12] for csDMARD)
among the propensity-matched cohorts. Incidence rates
(per 1000 PYs) were 4.34 [95% CI: 3.76, 5.02] and 3.87
[95% CI: 1.97, 8.73] among TNFi and csDMARD users,
respectively (Supplementary File 4, available at
Rheumatology online). There was no significant difference
in OJR rates between the exposure cohorts (Fig. 1)
FIG. 1 Estimated impact of TNFi on subsequent joint
replacement rates among matched TNFi and csDMARD
patients
csDMARD: conventional synthetic DMARD.
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Interactions
Age was found to be a significant (P < 0.001) effect modi-
fier for both THR and TKR outcomes, although disease
severity was not (P > 0.1). In subsequent stratified ana-
lyses (Supplementary File 5, available at Rheumatology
online), TNFi was associated with an estimated 40% re-
duction in incidence of THR among older patients (HR =
0.60 [95% CI: 0.41, 0.87; P = 0.008]) (Fig. 2). Differences in
THR or TKR incidence rates between TNFi and csDMARD
cohorts among younger patients were non-significant
(Fig. 2, Supplementary File 5, available at Rheumatology
online).
Sensitivity analyses
Results were unchanged when PS matching and subse-
quent survival analysis was repeated following exclusion
of (n= 1213) patients recruited into the TNFi cohort after
the csDMARD cohort had closed. Comparative effective-
ness estimates were HR = 0.81 (95% CI: 0.55, 1.18) for
THR and 1.11 (95% CI: 0.83, 1.50) for TKR. Results of
the sensitivity IV analysis (Supplementary Files 6 & 7,
available at Rheumatology online) confirmed main find-
ings, with a borderline reduction in risk of THR (absolute
risk reduction of 1.88 per 100 patients [95% CI: 3.86,
0.10; P = 0.063]) but no association between biologics use
and TKR risk (0.57 per 100 patients [95% CI: 2.69, 1.54;
P = 0.60]).
Discussion
Main findings
We have sought to address the scarcity of patient-level
data comparing use of TNFi vs csDMARDs on rates of
joint replacement in RA. Using a large UK-based RA bio-
logics register, overall we found no difference in subse-
quent rates of joint replacement between PS matched
TNFi and csDMARD users. When stratified by age, TNFi
was associated with a significant 40% reduction
(P = 0.008) in THR incidence among patients 560 years
old (Fig. 2), although non-significant increases were
observed in TKR for the same age group and in THR for
those <60 years old.
Findings in context
Our overall incidence rates of THR and TKR (results not
shown) of 4.95/1000 PYs and 7.84/1000 PYs, respect-
ively, align well with previous estimates of joint replace-
ment among RA patients within the UK [16] and elsewhere
[17, 26, 27].
Emerging observational data indicate that the number
and/or incidence of RA-related joint surgery has been in
decline across numerous developed countries [16, 17,
2737], although this has primarily been seen for smaller
joints [35, 3739]. Many of these studies have inferred a
possible role of biologics in this decline. Indeed, a reduc-
tion in need for joint replacement associated with TNFi
use would be an expected finding given previous evi-
dence of TNFi use reducing joint damage as measured
radiographically [15]. A previous meta-analysis of 70
RCT studies reported that annual radiographic progres-
sion was 0.6% less in patients treated with biologics com-
pared with those on a single DMARD [40]. Similarly,
another meta-analysis has demonstrated that patients
on initial combination therapy (methotrexate plus a bio-
logic agent) are 30% more likely to experience non-pro-
gression at 1-year than those on methotrexate alone [41].
In this context, a 40% reduction in THR rates associated
with TNFi use among a more elderly subgroup of patients
as found in the present study is quite plausible, and a lack
of translation of positive findings on joint erosion from
prior RCTs into a ‘real world’ reduction in rates of joint
replacement within our main study sample is initially
surprising.
However, a more detailed examination of prior RCT
findings indicate that an expectation of widespread reduc-
tion in joint replacement associated with TNFi use is po-
tentially unwarranted. There is a large degree of variation
in the nature of comparator groups used in prior studies
[42, 43], and this could be an important factor in consider-
ing the lack of effect as described in our main findings. For
instance, while RCT studies have shown reduced radio-
graphic progression among biologic users vs csDMARD
monotherapy, an almost equal reduction has been
achieved among combination csDMARD users relative
to csDMARD monotherapy [40]. Similarly, while TNFi has
been shown to confer early benefits over combination
csDMARD therapy, these benefits have been reported to
disappear during the second year of follow-up [44], pos-
sibly due to time-to-efficacy and time to achieve maximal
dose of csDMARDs. The use of etanercept (vs oral triple
therapy) resulted in only small radiographic benefits in an-
other trial [45], with another showing triple therapy to be
non-inferior to biologics in terms of change in DAS28 at
48 weeks [46]. Given these previous data, it could be that
the reduced THR rates in older patients may reflect a gen-
eral improvement in management of RA over the past
20 years and earlier and more aggressive use of
FIG. 2 Estimated impact of TNFi on subsequent joint re-
placement rates among matched TNFi and csDMARD
patients: stratified by age
csDMARD: conventional synthetic DMARD.
1172 https://academic.oup.com/rheumatology
Samuel Hawley et al.
csDMARDs rather than solely the effect of TNFi.
Intriguingly, a registry-based study on the topic [47] re-
cently found increased rates of major joint replacement
associated with use of biologic therapy, although the au-
thors concluded residual confounding was an issue given
the small number of confounding factors for which the
analysis was adjusted.
We found a reduction in THR incidence among an older
patient subgroup, but no significant impact on TKR inci-
dence, which is interesting as one might expect any effect
to be expressed approximately equally at hip and knee. It
could be that the relatively long disease duration at our
baseline meant there was greater potential for prevention
of joint destruction at the hip over knee, although details
of differential natural history of RA disease at these two
joints are not well established. It is also very difficult to
disentangle the impact of TNFi on improved function and
overall quality of life and how this may have mediated
effects on longer-term progression of joint damage, po-
tentially differentially at the knee and hip. Another factor
could be the role of trauma related THRs among the older
subgroup and whether there may be some pathway to
reduced THR rates via TNFi associated improvement in
bone quality. It should be emphasized, however, that the
positive impact on THR incidence was only observed in a
subgroup of patients that have not been well studied in
this regard previously and that prior studies at the popu-
lation-level have identified different patterns in this regard,
some finding reduced rates of TKR [16, 17] and others
THR [27, 34] following introduction of TNFi
Limitations
The potential for residual confounding by indication is a
key limitation of the current study. Given that prior to
matching there was a much higher disease severity
among the TNFi group (Supplementary File 2, available
at Rheumatology online), we cannot rule out that the
overall lack of reduction in joint replacement rates
among TNFi users may be due in part to a greater preva-
lence of unmeasured aspects of disease severity and
unresponsiveness to therapy in this group, thereby main-
taining a baseline ‘disadvantage’ even after PS match-
ing. On the other hand, estimates of the impact of TNFi
exposure may be subject to a general healthy user bias
in that a clinician perceives sufficient patient ability to
tolerate and benefit from more intensive therapy regi-
mens, which may have here contributed to the reduced
rate of THR in the older TNFi cohort. The use of an IV
approach as a sensitivity analysis sought to address the
issue of unmeasured confounding, in which the treat-
ment effect was estimated using clinician preference
for biologics as an IV, assuming this to be a strong pre-
dictor of exposure but unrelated/weakly-related to con-
founders of the TNFijoint replacement relationship.
However, the findings of this IV approach should be in-
terpreted with caution given the instrument was here
associated with several measured confounders
(Supplementary File 3, available at Rheumatology
online) which may undermine its validity as a means to
obtain unbiased estimates in the presence of unmeas-
ured confounding. The PS analytical approach taken, in
which comparable csDMARD matches were found for
each TNFi user—while much improving the internal val-
idity—does mean our findings are not average treatment
effects generalizable to the entire RA population but an
estimate of the ‘average treatment effect on the treated’
[48]. This is evident given that the csDMARD users
included in the matched sample had more established
and severe disease (thereby making them comparable to
the TNFi sample) than the unmatched csDMARD sample
(Supplementary File 2, available at Rheumatology
online). The study findings should also be interpreted in
the context of a relatively long median disease duration
at baseline (Table 1), which means they are not neces-
sarily generalizable to the context of early RA. Finally, we
relied on a combination of physician-reported and self-
reported incidence of THR, TKR and OJR for our study
outcomes as per BSRBR-RA follow-up questionnaires.
This may have introduced bias if events were under-re-
ported, although this would likely act non-differentially in
regard to TNFi status and minimally during the early
years of follow-up, during which time study participants
were sent questionnaires every six months. These vari-
ous limitations to the present analysis may partly explain
differences in the results obtained here compared with
previous ecological data on widespread reductions in
joint replacement rates in RA during the biologic era.
While a reduction in THR amongst older TNFi users
offers some support for biologics playing a role in redu-
cing need for joint replacement, it must also be noted
that the lack of an overall protective effect is suggestive
that other factors apart from TNFi are likely to be
involved in the aforementioned downward population
trends in joint replacement rates in RA.
Strengths
Our study’s key strengths are that BSRBR-RA is one of
the largest RA registers in the world, which made it pos-
sible for us to adjust for many potential confounders and
stratify analyses where there was significant effect modi-
fication. We were also able to accurately censor follow-
up given the linkage to Health and Social Care
Information Centre mortality data. The use of PS match-
ing is a strong method for dealing with bias [19] arising
from likely confounding by TNFi indication, and we were
able to reach good balance between the two exposure
groups in terms of baseline characteristics across most
variables.
Conclusion
In this large prospective study, we found no overall asso-
ciation between TNFi vs csDMARD therapy and subse-
quent incidence of joint replacement among RA
patients, although a 40% relative reduction in THR rates
was found among older patients. Future studies are
needed to confirm and/or further elucidate the relationship
between TNFi use and joint replacement.
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